This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
J-147
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST LOW
Compelling preclinical story — reversed cognitive deficits in old 3xTg-AD mice, reversed age-related cognitive decline in non-AD aged mice, longer healthspan in SAMP8 progeroid mice. But zero human RCTs. Research-chem supply is the same gray-market peptide-vendor channel as the rest of the high-risk longevity compounds, with unknown identity verification. ATP synthase is a load-bearing protein and chronic agonism in healthy humans is uncharacterized — the rodent benefit is in pathological context (AD, aging), not healthy-young, and there is no theoretical reason a young healthy mitochondrion benefits from a synthase agonist. Verdict: WATCH-LIST tracking Schubert lab + Abrexa Pharmaceuticals → if a Phase 1 healthy-volunteer trial reads out with safety + biomarker signal, revisit. For a 20yo healthy user there is no current case.
▸ Sourcing deep dive
Research-chem only. No FDA-approved form. Same supply chain quality concerns as other Salk-lineage investigational compounds (P7C3, P21).
▸ Verdict change log
- 2026-06-05 — Initial verdict WATCH-LIST. Pending human Phase 1 safety + PK data. (stub)
▸ Open questions / gaps Open
- Whether oral bioavailability + brain penetration in humans matches the rodent profile.
- Whether the AD-model + aged-mouse benefit translates to any signal in healthy young humans, or only matters in mitochondrial-decline pathology.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.